The specific characteristics of the CD19 cell marker make it an ideal therapeutic target in the treatment of B-cell lymphoma. Several molecules targeting CD19 have recently been made available, or are currently being developed, and show promising results for this therapeutic indication. This seems to be particularly true in the management of relapsing or refractory diffuse large B-cell lymphoma, as demonstrated by the results of the different studies described in this article. The choice of the right molecule and the best sequence for these treatments is still to be defined.
Key Words
Relapsing or refractory diffuse large B-cell lymphoma, anti-CD19 therapies